Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- DAWN
- Price
- 12.34
- Stock movement up
- +0.27 (2.24%)
- Company name
- Day One Biopharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.27B
- Ent value
- 1.29B
- Price/Sales
- 9.48
- Price/Book
- 2.81
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 0.82%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
DAWN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.48 |
| Price to Book | 2.81 |
| EV to Sales | 9.63 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 102.68M |
| EPS (TTM) | -1.47 |
| FCF per share (TTM) | -1.24 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 133.67M |
| Gross profit (TTM) | 119.56M |
| Operating income (TTM) | -165.62M |
| Net income (TTM) | -151.76M |
| EPS (TTM) | -1.47 |
| EPS (1y forward) | -0.65 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 89.44% |
| Operating margin (TTM) | -123.90% |
| Profit margin (TTM) | -113.53% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 43.28M |
| Net receivables | 16.70M |
| Total current assets | 489.97M |
| Goodwill | 0.00 |
| Intangible assets | 18.82M |
| Property, plant and equipment | 4.68M |
| Total assets | 513.78M |
| Accounts payable | 5.78M |
| Short/Current long term debt | 2.89M |
| Total current liabilities | 56.47M |
| Total liabilities | 62.91M |
| Shareholder's equity | 450.87M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -119.62M |
| Capital expenditures (TTM) | 8.73M |
| Free cash flow (TTM) | -128.35M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -33.66% |
| Return on Assets | -29.54% |
| Return on Invested Capital | -33.65% |
| Cash Return on Invested Capital | -28.46% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.20 |
| Daily high | 13.14 |
| Daily low | 11.97 |
| Daily Volume | 3.48M |
| All-time high | 27.92 |
| 1y analyst estimate | 22.25 |
| Beta | -1.28 |
| EPS (TTM) | -1.47 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 9 Mar 2026 |
Downside potential
Loading...
Downside potential data
| DAWN | S&P500 | |
| Current price drop from All-time high | -55.80% | -0.89% |
| Highest price drop | -79.23% | -19.00% |
| Date of highest drop | 6 Aug 2025 | 8 Apr 2025 |
| Avg drop from high | -66.64% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.27B
Marketcap category
Small-cap
Description
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Employees
184
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page